-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 21, Teyi Pharmaceuticals issued an announcement stating that the company had recently obtained the "Notice of Supplementary Application Approval for Compound Sulfamethoxazole Tablets" approved and issued by the National Medical Products Administration.
Compound sulfamethoxazole tablets are sulfa antibacterial drugs, which are a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP).
Compound sulfamethoxazole tablets are national essential drugs, Class A drugs in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)"